Cytos Biotechnology AG

DGAP-News: Cytos Biotechnology Ltd announces terms for capital increase

EQS Group-News: Cytos Biotechnology AG / Key word(s): Capital Increase
Cytos Biotechnology Ltd announces terms for capital increase

05.11.2013 / 07:00

---------------------------------------------------------------------

This media release and the information contained herein is not being issued
in and may not be distributed directly or indirectly in certain countries,
including the United States, Canada, Australia, Hong Kong, Japan, New
Zealand, Singapore, South Africa or any other jurisdiction where it might
be unlawful to do so. This media release does not constitute an offer for
the sale of securities.

Cytos Biotechnology announces terms for capital increase

New registered shares are issued for CHF 3.00; 32 existing shares entitle
to subscribe for
9 new shares

Schlieren (Zurich), Switzerland, November 5, 2013 - Cytos Biotechnology AG
(SIX:CYTN) ('Cytos') has announced the terms for a capital increase in the
form of a rights offering as follows: Shares are issued for CHF 3.00 and 32
existing shares entitle to subscribe for 9 new registered shares. Cytos
shareholders will receive additional information regarding the exercise of
the subscription rights via their bank or broker in the coming days.
Shareholders interested to subscribe shares beyond their subscription
rights must contact the Company's CFO Harry Welten (harry.welten@cytos.com;
Telephone: +41 (0)44 733 46 46) until November 13, 2013.

As previously announced, the group of institutional and strategic
shareholders that invested in the Company in 2012, namely Abingworth,
venBio, Aisling and Amgen, will increase their investment by CHF 9 million
as part of the rights offering. The Company's board of directors intends to
make available to new investors any shares that are not subscribed by the
current shareholders in the rights offering.

The following timetable is expected for the capital increase:



November 5,   Last trading day in existing shares incl. rights
2013
November 6,   First trading day in existing shares ex-rights, start of
2013          rights exercise period
November 15,  End of rights exercise period (12.00 CET)
2013
November 20,  Listing of new shares from rights issue
2013
November 21,  Payment and settlement
2013




The offering and listing prospectus dated November 5, 2013 is solely
relevant for the capital increase. This prospectus is available free of
charge from the Company (Telephone: +41 (0)44 733 47 47, facsimile: +41
(0)44 733 47 40, e-mail: info@cytos.com).

If fully subscribed, the share placement is expected to result in the
issuance of up to 6,303,215 new registered Cytos-shares with a nominal
value of CHF 0.10 each.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
novel, first-in-class, immune modulator in Phase 2 clinical development as
a potential new treatment for asthma.CYT003 has a novel mechanism of action
that inhibits the immune response that causes asthma, and may therefore be
beneficial for the control of asthma. In a successfully completed Phase 2a
study, CYT003 was shown to maintain asthma control and lung function in
patients with persistent allergic asthma, despite withdrawal of standard
therapy with inhaled corticosteroids. CYT003 has been shown to have a good
safety and tolerability profile in more than 450 individuals receiving the
active agent so far.Cytos was founded in 1995 as a spinoff from the Swiss
Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren
(Zurich), Switzerland. The Company is listed according to the Main Standard
on the SIX Swiss Exchange Ltd under the symbol CYTN.

www.cytos.com

Disclaimer
This document does neither constitute an offer to buy or to subscribe for
securities of Cytos Biotechnology Ltd nor a prospectus within the meaning
of applicable Swiss law. Investors should make their decision to buy or to
subscribe to securities of Cytos Biotechnology Ltd solely based on the
official offering and listing prospectus which will be published by Cytos
Biotechnology Ltd. Investors are furthermore advised to consult their bank
or financial adviser before making any investment decision. This document
does not constitute a prospectus pursuant to article 652a or 1156 of the
Swiss Code of Obligations or article 27 et seq. of the listing rules of the
SIX Swiss Exchange Ltd. A decision to invest in securities of Cytos
Biotechnology Ltd should be based exclusively on the offering and listing
prospectus published by Cytos Biotechnology Ltd for such purpose.
The securities described herein are offered publicly in Switzerland only.
The information contained herein shall not constitute an offer to sell or
the solicitation of an offer to buy, in any jurisdiction in which such
offer or solicitation would be unlawful prior to registration, exemption
from registration or qualification under the securities laws of any
jurisdiction.
This document is not being issued in the United States of America, Canada,
Australia, Hong Kong, Japan, New Zealand, Singapore, South Africa or any
other jurisdiction where it might be unlawful to do so and should not be
distributed or otherwise transmitted into the United States, or any other
of the aforementioned jurisdictions, or to U.S. persons (as defined in the
U.S. Securities Act of 1933, as amended) or publications with a general
circulation in the United States or any other of the aforementioned
jurisdictions. This document does not constitute an offer or invitation to
subscribe for or to purchase any securities in the United States of America
or any other jurisdiction. Securities may not be offered or sold in the
United States of America absent registration or an exemption from
registration under the U.S. Securities Act of 1933.

Forward Looking Statements

This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements.  You are urged to consider
statements that include the words 'will' or 'expect' or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, including that CYT003
may not demonstrate safety or efficacy in clinical trials, that there may
be delays in development or that CYT003 may not receive marketing approval,
and that the Company relies on outside financing to meet capital
requirements, which may not be available under acceptable terms or at all.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.





End of Corporate News

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=UCYURUVIIE

Document title: Cytos_Press_E_131105

---------------------------------------------------------------------

05.11.2013 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
             Open Market ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
237764 05.11.2013
 

 


Das könnte Sie auch interessieren: